Immunovia AB (IMMVF)
OTHER OTC:IMMVF
IMMVF Stock Chart & Stats
$0.05
-$0.10(-66.67%)
At close: 4:00 PM EST
$0.05
-$0.10(-66.67%)
Day’s Range― - ―
52-Week Range$0.02 - $0.04
Previous CloseN/A
Volume500.00
Average Volume (3M)0.00
Market Cap
$11.53M
Enterprise Value-$20.98M
Total Cash (Recent Filing)$77.46M
Total Debt (Recent Filing)$857.00K
Price to Earnings (P/E)―
Beta0.07
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding672,666,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)114.10
P/FCF Ratio-1.00
Enterprise Value/Market Cap-1.82
Enterprise Value/Revenue-30.67
Enterprise Value/Gross Profit1.31
Enterprise Value/Ebitda0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$887.67K
Bulls Say, Bears Say
Bulls Say
Strong Scientific And Clinical ValidationMultiple peer-reviewed studies and repeated podium selections create durable scientific credibility that supports clinician adoption, payer assessment and guideline consideration. This validation reduces clinical adoption risk and underpins long-term demand potential for the diagnostic test.
Secured Medicare Pricing And Billing CodeAn established Medicare price and billing code provide a structural foundation for per-test economics once coverage is granted. This durable pricing anchor can enable predictable revenue per unit and improve commercial negotiations with labs and health systems over the medium term.
Improved Funding And Cost DisciplineA recent capital raise plus disciplined cost cuts reduced monthly cash burn and narrowed losses, extending operational runway. Lower leverage and focused spending improve near-term survival odds and buy time to execute commercialization and evidence-generation plans.
Bears Say
Very Small And Declining Revenue BaseTiny and shrinking revenues mean the business has not yet demonstrated scalable commercial traction. Persistent low top-line undermines ability to absorb fixed costs, delays positive operating leverage, and keeps long-term profitability contingent on successful market ramp and coverage wins.
Negative Free Cash Flow And Ongoing Cash BurnConsistent negative operating and free cash flows force reliance on external financing. This raises dilution and refinancing risk and limits strategic flexibility; sustained negative cash generation undermines the company’s ability to scale commercial operations without further capital.
Coverage Not Yet Secured; Timing UncertainReimbursement decisions, not just pricing, determine realized revenue. Unsecured payer coverage creates structural revenue timing risk: even with a set Medicare price, widespread collections and predictable volumes depend on completed coverage reviews and payer adoption over months to years.
Immunovia AB News
IMMVF FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was $0.02 and its highest was $0.04 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is $11.53M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is May 07, 2026 which is in 39 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Feb 24, 2026. The company reported -$0.003 earnings per share for the quarter, beating the consensus estimate of -$0.004 by <$0.001.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -$0.003 in its last earnings report, beating expectations of -$0.004. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in IMMVF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
IMMVF Company Deck
IMMVF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful commercial, scientific and reimbursement progress: a successful product launch, strong clinical publications and podium presence, an awarded Medicare pricing of USD 897, state approvals in 48 states, targeted hiring of account managers, and a completed rights issue that improved cash position. However, near-term revenue remains limited, full payer coverage is not yet granted, cash runway extends only to Q3 2026 without additional capital, and realized per-test pricing and collections are still uncertain. The company emphasized disciplined spending, planned clinical utility data collection (including a 400-patient registry) and a mid-2026 Medicare submission with rolling data updates to mitigate coverage risk.View all IMMVF earnings summariesTechnical Analysis
Alligator Bioscience AB
―
Prostatype Genomics AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Klaria Pharma Holding AB
―